Evidence of a Causal Association Between Cancer and Alzheimer’s Disease: a Mendelian Randomization Analysis

Evidence of a Causal Association Between Cancer and Alzheimer’s Disease: a Mendelian Randomization Analysis

While limited observational evidence suggests that cancer survivors have a decreased risk of developing Alzheimer’s disease (AD), and vice versa, it is not clear whether this relationship is causal. Using a Mendelian randomization approach that provides evidence of causality, we found that genetically predicted lung cancer (OR 0.91, 95% CI 0.84–0.99, p = 0.019), leukemia (OR 0.98, 95% CI 0.96–0.995, p = 0.012), and breast cancer (OR 0.94, 95% CI…

Breast cancer survivors have lower risk of fatal disease, experts say

Breast cancer survivors have an 8% lower risk of developing Alzheimer's disease compared with cancer-free people, according to a medical journal.

Is Alzheimer's Risk Less in Cancer Survivors?

(MedPage Today) -- Breast cancer survivors had a slightly lower risk of Alzheimer's dementia than cancer-free people, a population-based cohort study in Korea showed. Over a median follow-up of 7 years, breast cancer survivors had an 8% lower...

Breast cancer survivors may have a lower risk of Alzheimer’s disease, experts say

South Korean researchers say they had found an 8 percent lower risk

Alzheimer’s Disease Risk in Breast Cancer Survivors: New Insights

In a counterintuitive twist to longstanding concerns about cognitive health following cancer treatment, a groundbreaking cohort study has revealed that breast cancer survivors may actually enjoy a reduced risk of developing Alzheimer’s dementia compared to individuals without a cancer history. Published in the reputable JAMA Network Open, this research challenges widely held assumptions about the neurotoxic effects of cancer therapies and posits…

#Advancements in Troculeucel Therapy A Potential Breakthrough for Post-Stroke and Alzheimer?s Patients

'Abstract:' NKGen Biotech is at the forefront of developing innovative cellular therapies, including Troculeucel, which shows promise in treating post-stroke and Alzheimer's disease (AD) patients. Recent advancements include the administration of Troculeucel to a stroke patient under an FDA-cleared compassionate use program and positive Phase 1 clinical trial results demonstrating improved cognitive outcomes in moderate Alzheimer's patients. Add…